Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 110pembrolizumab 92Pemetrexed 84Cisplatin 69Specimen Handling 40Paclitaxel 36durvalumab 35Docetaxel 34atezolizumab 33Nivolumab 33osimertinib 30Magnetic Resonance Spectroscopy 29Gemcitabine 22Radiotherapy 20Etoposide 20130-nm albumin-bound paclitaxel 19Cetuximab 16amivantamab 14Platinum 13Bevacizumab 13Radiosurgery 12Radiation 12lazertinib 11Taxes 11Ipilimumab 11Immunoglobulin G 11cemiplimab 10Topotecan 10Disulfides 101,2-diaminocyclohexaneplatinum II citrate 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paroxetine × Thoracic × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡